Aardvark Therapeutics Common Stock Return on Equity

Aardvark Therapeutics Common Stock (AARD) currently reports a ROE of -93.44%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Aardvark Therapeutics Common Stock's ROE history and peer comparisons.

Aardvark Therapeutics Common Stock's ROE of -93.44% is lower than the Healthcare sector average of 11.15%. That is roughly 937.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Aardvark Therapeutics Common Stock's current -93.44% should be judged against Healthcare norms (sector average: 11.15%) and against AARD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -93.44%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Aardvark Therapeutics Common Stock, and consider following AARD for alerts when major investors trade the stock.

Aardvark Therapeutics Common Stock is classified in the Healthcare sector. On ROE, it currently shows -93.44% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AARD with unrelated industries.